Annette Tobia, Ph.D., J.D.
Founder & CEO
Dynamis Therapeutics and Dynamis Skin Science
Founding and running her own company was inevitable for Dr. Annette M. Tobia who, in addition to her Ph.D. in molecular biology, holds a law degree from Rutgers University. She began her career as a post-doctoral American Cancer Society Fellow at Rockefeller University. From there she became counsel to the president of the Bristol Myers Institute for Medical Research where she structured strategic alliances with biotech companies and academic institutions. Annette next went on to serve as senior vice president and general counsel and founder of British Technology Group, USA (BTG), one of the world's leading technology transfer and licensing companies. She was also managing director of its parent company, BTG plc, a United Kingdom-based company.
Her next stop - as a formal entrepreneur - was as a co-founder of QED Technologies which started and administered virtual companies for venture capital firms. While there, she was acting president of Arcturus Pharmaceutical Co., a dermatology company founded by three Harvard dermatologists and funded by several Boston venture capitalists.
In 1997, because of her extensive experience as founder and manager of start-up companies, Dr. Tobia was asked by Fox Chase Cancer Center to form a company around a promising new discovery, still in its early R&D stage. The research focused on the discovery of a likely contributor to the complications of diabetes and aging and the development of a new drug that would help prevent and mediate their complications. Dynamis continues its drug screening program for a treatment of diabetic kidney disease.
Recently, it was serendipitously discovered, during a diabetes study, that the drug being tested actually resulted in smooth and elastic skin. Dr. Tobia raised monies to bring an effective anti-aging, anti-wrinkling cream to the cosmetic marketplace that targets the original FCCC drug target.
Dynamis Skin Science was then formed to launch and sell MEG 21, an effective anti-aging, anti-wrinkling product line to consumers through high end dermatologists, plastic surgeons and spas through out the United States, Mexico, and Guatemala. MEG 21 is sold through chain stores in Hong Kong and Macau and will be soon launched in China through a strategic partnership in Hong Kong.
Over the past 11 years, Dr. Tobia has raised more than $8.5 million from a combination of strategic partnerships, venture capitalists and SBIR grants.